3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Hepatocellular
59
Cholangiocarcinoma
19
Carcinoma, Renal Cell
16
Biliary Tract Neoplasms
11
Stomach Neoplasms
9
Thyroid Neoplasms
8
Endometrial Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasms
7
Melanoma
6
Uterine Cervical Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Neuroendocrine Tumors
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Brain Neoplasms
3
Advanced Biliary Tract Cancer
3
Adenocarcinoma, Follicular
3
Vulvar Neoplasms
2
Uveal Melanoma
2
Triple Negative Breast Neoplasms
2
Thymoma
2
Solid Tumors
2
Interventions
Sunitinib
5
pembrolizumab
4
Paclitaxel
4
Carboplatin
4
Radiotherapy
3
Cyclophosphamide
3
Cisplatin
3
selinexor
2
lenvatinib
2
Taxes
2
Ramucirumab
2
Octreotide
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Erlotinib Hydrochloride
2
Chemoradiotherapy
2
zimberelimab
1
saracatinib
1
regorafenib
1
epacadostat
1
envafolimab
1
belinostat
1
avelumab
1
atezolizumab
1
amrubicin
1
alovudine
1
TP protocol
1
Radiofrequency Ablation
1
Radiation Dose Hypofractionation
1
Prednisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Thymoma
×
lenvatinib
×
Clear all
NCT04710628
2026-02-19
PECATI
MedSIR
Phase 2
Completed
43 enrolled
NCT05832827
2023-10-23
Artemis
National Cancer Center, Japan
Phase 2
Recruiting
35 enrolled